|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-tieulent J and Jemal A: Global Cancer statistics, 2012. Ca
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Latifi A, Luwor RB, Bilandzic M,
Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA,
Findlay JK and Ahmed N: Isolation and characterization of tumor
cells from the ascites of ovarian cancer patients: Molecular
phenotype of chemoresistant ovarian tumors. PLoS One. 7:e468582012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Su Z, Graybill WS and Zhu Y: Detection and
monitoring of ovarian cancer. Clin Chim Acta. 415:341–345. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Têtu B, Popa I, Bairati I, L'Esperance S,
Bachvarova M, Plante M, Harel F and Bachvarov D:
Immunohistochemical analysis of possible chemoresistance markers
identified by micro-arrays on serous ovarian carcinomas. Mod
Pathol. 21:1002–1010. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Dowdy S, Tipton T, Podratz K, Lu WG,
Xie X and Jiang SW: HE4 as a biomarker for ovarian and endometrial
cancer management. Expert Rev Mol Diagn. 9:555–566. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rein BJ, Gupta S, Dada R, Safi J, Michener
C and Agarwal A: Potential markers for detection and monitoring of
ovarian cancer. J Oncol. 2011:4759832011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nguyen L, Cardenas-Goicoechea SJ, Gordon
P, Curtin C, Momeni M, Chuang L and Fishman D: Biomarkers for early
detection of ovarian cancer. Womens Health (Lond). 9:171–187. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Toss A, de Matteis E, Rossi E, Casa LD,
Iannone A, Federico M and Cortesi L: Ovarian cancer: Can proteomics
give new insights for therapy and diagnosis? Int J Mol Sci.
14:8271–8290. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
An HJ, Kim DS, Park YK, Kim SK, Choi YP,
Kang S, Ding B and Cho NH: Comparative proteomics of ovarian
epithelial tumors. J Proteome Res. 5:1082–1090. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cortesi L, Rossi E, Casa L Della,
Barchetti A, Nicoli A, Piana S, Abrate M, La Sala GB, Federico M
and Iannone A: Protein expression patterns associated with advanced
stage ovarian cancer. Electrophoresis. 32:1992–2003. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Faça VM, Ventura AP, Fitzgibbon MP,
Pereira-Faça SR, Pitteri SJ, Green AE, Ireton RC, Zhang Q, Wang H,
O'Briant KC, et al: Proteomic analysis of ovarian cancer cells
reveals dynamic processes of protein secretion and shedding of
extra-cellular domains. PLoS One. 3:e24252008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jackson D, Craven RA, Hutson RC, Graze I,
Lueth P, Tonge RP, Hartley JL, Nickson JA, Rayner SJ, Johnston C,
et al: Proteomic profiling identifies afamin as a potential
biomarker for ovarian cancer. Clin Cancer Res. 13:7370–7379. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li XQ, Zhang SL, Cai Z, Zhou Y, Ye TM and
Chiu JF: Proteomic identification of tumor-associated protein in
ovarian serous cystadenocarinoma. Cancer Lett. 275:109–116. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Petri AL, Simonsen AH, Yip TT, Hogdall E,
Fung ET, Lundvall L and Hogdall C: Three new potential ovarian
cancer biomarkers detected in human urine with equalizer bead
technology. Acta Obstet Gynecol Scand. 88:18–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gunawardana CG, Kuk C, Smith CR, Batruch
I, Soosaipillai A and Diamandis EP: Comprehensive analysis of
conditioned media from ovarian cancer cell lines identifies novel
candidate markers of epithelial ovarian cancer. J Proteome Res.
8:4705–4713. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang Y, Xu B, Liu Y, Yao H, Lu N, Li B,
Gao J, Guo S, Han N, Qi J, et al: The ovarian cancer-derived
secretory/releasing proteome: A repertoire of tumor markers.
Proteomics. 12:1883–1891. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gluck F, Hoogland C, Antinori P, Robin X,
Nikitin F, Zufferey A, Pasquarello C, Fétaud V, Dayon L, Muller M,
et al: EasyProt-an easy-to-use graphical platform for proteomics
data analysis. J Proteomics. 79:146–160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Epiney M, Ribaux P, Arboit P, Irion O and
Cohen M: Comparative analysis of secreted proteins from normal and
preeclamptic trophoblastic cells using proteomic approaches. J
Proteomics. 75:1771–1777. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Akyol S, Gercel-Taylor C, Reynolds LC and
Taylor DD: HSP-10 in ovarian cancer: Expression and suppression of
T-cell signaling. Gynecol Oncol. 101:481–486. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chambers SK: Role of CSF-1 in progression
of epithelial ovarian cancer. Future Oncol. 5:1429–1440. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chambers SK, Kacinski BM, Ivins CM and
Carcangiu ML: Overexpression of epithelial macrophage
colony-stimulating factor (CSF-1) and CSF-1 receptor: A poor
prognostic factor in epithelial ovarian cancer, contrasted with a
protective effect of stromal CSF-1. Clin Cancer Res. 3:999–1007.
1997.PubMed/NCBI
|
|
22
|
Lim HY, Ho QS, Low J, Choolani M and Wong
KP: Respiratory competent mitochondria in human ovarian and
peritoneal cancer. Mitochondrion. 11:437–443. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang H, Rosen DG, Wang H, Fuller GN, Zhang
W and Liu J: Insulin-like growth factor-binding protein 2 and 5 are
differentially regulated in ovarian cancer of different histologic
types. Mod Pathol. 19:1149–1156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chambers SK, Wang Y, Gertz RE and Kacinski
BM: Macrophage colony-stimulating factor mediates invasion of
ovarian cancer cells through urokinase. Cancer Res. 55:1578–1585.
1995.PubMed/NCBI
|
|
25
|
Toy EP, Azodi M, Folk NL, Zito CM, Zeiss
CJ and Chambers SK: Enhanced ovarian cancer tumorigenesis and
metastasis by the macrophage colony-stimulating factor. Neoplasia.
11:136–144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lancaster JM, Sayer RA, Blanchette C,
Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW,
Marks JR and Berchuck A: High expression of insulin-like growth
factor binding protein-2 messenger RNA in epithelial ovarian
cancers produces elevated preoperative serum levels. Int J Gynecol
Cancer. 16:1529–1535. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
David S, Bucchieri F, Corrao S, Czarnecka
AM, Campanella C, Farina F, Peri G, Tomasello G, Sciumè C, Modica
G, et al: Hsp10: Anatomic distribution, functions, and involvement
in human disease. Front Biosci. 5:768–778. 2013. View Article : Google Scholar
|
|
28
|
Niehrs C: Function and biological roles of
the Dickkopf family of Wnt modulators. Oncogene. 25:7469–7481.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Veeck J and Dahl E: Targeting the Wnt
pathway in cancer: The emerging role of Dickkopf-3. Biochim Biophys
Acta. 1825:18–28. 2012.PubMed/NCBI
|
|
30
|
Jiang T, Huang L, Wang S and Zhang S:
Clinical significance of serum Dkk-3 in patients with gynecological
cancer. J Obstet Gynaecol Res. 36:769–773. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Silacci P, Mazzolai L, Gauci C,
Stergiopulos N, Yin HL and Hayoz D: Gelsolin superfamily proteins:
Key regulators of cellular functions. Cell Mol Life Sci.
61:2614–2623. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Spinardi L and Witke W: Gelsolin and
diseases. Subcell Biochem. 45:55–69. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Noske A, Denkert C, Schober H, Sers C,
Zhumabayeva B, Weichert W, Dietel M and Wiechen K: Loss of Gelsolin
expression in human ovarian carcinomas. Eur J Cancer. 41:461–469.
2005. View Article : Google Scholar : PubMed/NCBI
|
